mProX™ Human FLT4 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1148	Magic™ Human FLT4(VEGFR3) in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

FLT4

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Cardiovascular Research; Lymphatic Malformation 1 and Congenital Heart Defects,

Related Diseases

Lymphatic Malformation 1 and Congenital Heart Defects, Multiple Types, 7. Among its related pathways are Apoptotic Pathways in Synovial Fibroblasts and GPCR Pathway

Gene ID

2324

UniProt ID

P35916

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The vascular endothelial growth factor receptor 3 (VEGFR-3) protein, which controls the growth and upkeep of the lymphatic system, is made by the FLT4 gene. The body's lymphatic system creates and distributes immune cells and fluids. Two proteins known as vascular endothelial growth factor C (VEGF-C) and vascular endothelial growth factor D (VEGF-D) activate (turn on) VEGFR-3. The attachment of VEGF-C and VEGF-D to VEGFR-3 results in the production of chemical signals that control lymphatic cell growth, migration, and survival. The customized FLT4 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Rebecca

I recently utilized the FLT4 cell line from Creative Biolabs. This cell line proved to be an exceptional targeting tool for my research. Jun 29 2021

chat Verified Customer

chat Emily

The FLT4 cell line has been crucial in elucidating the receptor's role in various biological processes. Apr 05 2022

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 KDR and FLT4 in HDMECs, HUVECs and leukemia cell lines.

Quantitative real-time PCR was used to quantify the KDR and FLT4 mRNA expression levels, which are listed beneath the cell line name. The endogenous control utilized in this study was TBP expression, whereas the normalization cell lines employed were CMK (KDR) and HEL (FLT4).

Ref: Quentmeier, Hilmar, et al. "DNA methylation regulates expression of VEGF-R2 (KDR) and VEGF-R3 (FLT4)." BMC cancer 12.1 (2012): 1-10.

Pubmed: 22251800

DOI: 10.1186/1471-2407-12-19

Research Highlights

Coordinated expression of multiple essential regulators is necessary for the formation of the lymphatic system, including vascular endothelial growth factor C (VEGFC), its receptor FLT4, and a crucial transcriptional effector called PROX1.
Gauvrit, Sébastien, et al. "HHEX is a transcriptional regulator of the VEGFC/FLT4/PROX1 signaling axis during vascular development." Nature communications 9.1 (2018): 2704.
Pubmed: 30006544 DOI: 10.1038/s41467-018-05039-1

In macrophages harboring the mutant FLT4, the AMPK agonist AICAR may be able to reverse glycolytic reprogramming and inflammasome activation. This could have translational implications for patients with Flt4 mutations, as it may help prevent repeated infections.
Ma, Li, et al. "FLT4/VEGFR3 activates AMPK to coordinate glycometabolic reprogramming with autophagy and inflammasome activation for bacterial elimination." Autophagy 18.6 (2022): 1385-1400.
Pubmed: 34632918 DOI: 10.1080/15548627.2021.1985338